文献速递头颈部肿瘤放疗

风险适配的个体化放疗靶区选择在原发灶不明头颈癌中的评估

Evaluation of risk-tailored individualized selection of radiation therapy target volume for head and neck carcinoma of unknown primary.
PubMed 文献 · Radiother Oncol · 2022-07-26

本研究回顾了2005至2018年接受根治性IMRT的风险适配靶区治疗的203例原发灶不明头颈癌(HNCUP)患者,中位随访5年,5年局部失败、区域失败、远处转移、总生存和≥3级晚期毒性分别为3%、14%、10%、79%和7%;多变量分析显示cN2c-N3、HPV阴性和年龄较大为总生存较差的预测因素。

要点

  • 风险适配IMRT靶区缩减后5年局部失败3%、区域失败14%、总生存79%。
  • 4例黏膜复发中3例位于选择性黏膜CTV内、1例位于其边缘。
  • cN2c-N3、HPV阴性和年龄较大与较差总生存相关。

核心结论

  • 根治性IMRT联合风险适配的放疗体积缩减治疗HNCUP获得了高概率的肿瘤控制,且晚期毒性发生率可接受。

研究设计与样本

  • 回顾性分析2005至2018年接受根治性IMRT的203例HNCUP患者,分析局部失败、区域失败、远处转移、总生存和≥3级晚期毒性,并用多变量分析寻找总生存预测因素。

主要发现

  • 203例中cN1占7%、cN2a占14%、cN2b占46%、cN2c占14%、cN3占19%。
  • 118例已知HPV状态(通过p16染色)的患者中81例(68%)为阳性。
  • IMRT靶区分别避开了对侧扁桃体(55%)、下咽双侧或对侧(72%)、鼻咽(72%)、喉(87%)和对侧未受累颈部(21%)。
  • 中位随访5年,5年局部失败、区域失败、远处转移、总生存和≥3级晚期毒性分别为3%、14%、10%、79%和7%。
  • 4例发生黏膜复发:3例在选择性黏膜CTV内,1例在其边缘;同侧颈部照射患者无一在对侧未受累颈部失败。

关键数值与推荐

  • 多变量分析确定cN2c-N3、HPV阴性状态和年龄较大为总生存较差的预测因素。
  • 在cN2-3亚组(n=189)中,cN2c-N3、HPV阴性状态和年龄较大预测较低总生存,而同步化疗与较好总生存相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intensity-modulated radiation therapy (IMRT) has enabled risk-tailored approach to elective mucosal and nodal clinical target volumes (CTVs) in treatment of head and neck carcinoma of unknown primary (HNCUP). This study report outcomes following such approach. METHODS: HNCUP patients treated with definitive IMRT between 2005 and 2018 were reviewed. Local failure (LF), regional failure (RF), distant metastasis (DM), overall survival (OS) and grade ≥3 late toxicity (LT) were analyzed. Multivariable analysis (MVA) was used to identify OS predictors for entire cohort and cN2-3 subgroup. RESULTS: A total of 203 patients were eligible: cN1 (7%), cN2a (14%), cN2b (46%), cN2c (14%) and cN3 (19%). Among 118 patients with known HPV status (by p16 staining), 81 (68%) were positive. IMRT target volume spared contralateral tonsil (55%), bilateral or contralateral sides of hypopharynx (72%), nasopharynx (72%), larynx (87%) and contralateral uninvolved neck (21%). Median follow-up was 5 years. Five-year LF, RF, DM, OS, and LT were 3%, 14%, 10%, 79%, and 7% respectively. Four patients developed mucosal recurrence: 3 within and 1 at the margin of the elective mucosal CTV. None of ipsilateral neck irradiation patients failed in the contralateral uninvolved neck. MVA identified cN2c-N3, HPV-negative status and older age as predictors for inferior OS. Within cN2-3 subgroup (n = 189): cN2c-N3, HPV-negative status and older age predicted lower OS, while concurrent chemotherapy was associated with better OS. CONCLUSION: Definitive IMRT with risk-adaptive radiation volume de-escalation for HNCUP resulted in high probability of tumor control with acceptable rate of late toxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Ghatasheh H, Huang SH, Su J, et al. Evaluation of risk-tailored individualized selection of radiation therapy target volume for head and neck carcinoma of unknown primary. Radiother Oncol. 2022. PMID: 35905781. doi:10.1016/j.radonc.2022.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。